We compared the results of autologous and allogeneic peripheral blood hematopoietic cell transplant (HCT) in 87 patients with multiple myeloma using myeloablative preparative regimen. Autologous transplant (n ¼ 70) led to a lower 100-day transplant-related mortality (TRM) of 4% [0-9%] PBSCT High-dose chemo/radiotherapy followed by autologous stem cell transplant has been associated with improved response rates and survival in patients with multiple myeloma with median overall survival (OS) and progression-free survival (PFS) of 43-68 and 21-43 months, respectively.
PBSCT
High-dose chemo/radiotherapy followed by autologous stem cell transplant has been associated with improved response rates and survival in patients with multiple myeloma with median overall survival (OS) and progression-free survival (PFS) of 43-68 and 21-43 months, respectively. [1] [2] [3] [4] [5] [6] Further intensification with sequential or tandem transplantation attempting to further increase complete responses (CR), and enhance long-term survival has been reported in numerous series [4] [5] [6] and remains under study. A randomized comparison of single vs double transplants in patients with early myeloma showed superior results with double transplants (7-year probability of OS and event-free survival of 42 and 20% in the doubletransplant arm vs 21 and 10% in the single-transplant arm 5 ). However, following autologous transplantation, almost all patients eventually relapse or have progressive disease. Allogeneic myeloablative transplants offer the added potential for a cure through a graft vs myeloma effect, but have been limited due to high transplant-related mortality (TRM) of over 40%. 2, 7, 8 However, a recent update from the EBMT registry suggested a lower TRM of 21% at 6 months. 7 Nonmyeloablative transplants have been reported in phase II studies to be associated with lower mortality (1-year TRM of 15%), but need longer follow-up to assess their full impact. 9 We compared clinical outcomes of 70 patients who underwent autologous peripheral blood stem cell transplant (PBSCT) and 17 consecutive patients who underwent allogeneic myeloablative transplants for myeloma, and present an analysis designed to identify the most suitable candidates for either approach.
Methods
Transplant candidates had histologically proven stage II or III multiple myeloma. Patients after initial therapy were eligible with either responsive or nonresponsive disease. However, relapsed patients had to be chemosensitive (objectively responding to salvage chemotherapy) in order to be eligible for transplantation. Younger patients p55 years with a Karnofsky performance status 480% with either high-risk disease, poor stem cell mobilization or poor response to initial chemotherapy and satisfactory organ function were eligible for allogeneic transplant provided they had an HLA-matched sibling donor. Other patients up to 70 years of age lacking a matched donor underwent an autologous transplant. Eligible patients were required to be at least 4 weeks from prior chemotherapy (6 weeks after nitrosourea therapy) before enrollment. All patients signed a written informed consent prior to transplant. A total of 87 consecutive patients underwent transplantation between 1993 and 2003: 70 patients underwent an autologous transplant and 17 patients underwent a matched sibling donor allogeneic transplant after myeloablative preparative regimen.
Patients undergoing autologous PBSCT received two cycles of priming chemotherapy with growth factor mobilization followed by PBSC collections. Patients were randomized to receive either GM-CSF or G-CSF after priming chemotherapy. The results of this randomized trial (CD34 þ cell dose collected and engraftment) have been described previously. 10 Each cycle included cyclophosphamide 4 gm/m 2 intravenously (i.v.) on day 1, mitoxantrone 8 mg/m 2 i.v. over 1 h on days 1 and 2, dexamethasone (20 mg/m 2 i.v.) every 12 h in four doses on days 1 and 2. The daily administration of cytokine (starting day 4) was randomly assigned to either G-CSF (250 mg/m 2 /day subcutaneously) or GM-CSF (250 mg/m 2 /day subcutaneously) until PBSC collections were complete. PBSC collections were performed aiming for a target collection of 5 million CD34 þ cells/kg (minimum 2 million CD34 þ cells/kg). Following PBSC collections for cycle 1, 51 patients received cycle 2 mobilization using the same chemotherapy and were assigned cytokine with additional aphereses after neutrophil recovery to X700/ml. The second cycle of priming chemotherapy was deferred in 19 patients due to extremely low CD34 þ cell collections, toxicity or patient refusal. In case of inadequate collection of CD34 þ progenitors, after a rest period of 1-2 weeks and full hematologic recovery, collection was attempted using the originally randomized cytokine alone administered for 5-8 days prior to apheresis.
The pretransplant myeloablative preparative regimen for patients undergoing autologous transplant included cyclophosphamide 75 mg/kg i.v. Â 2 days, followed by fractio- All allogeneic donors were HLA-identical siblings. Allografts were mobilized using daily G-CSF at 7.5 mg/kg until aphereses were complete. 11 The pretransplant highdose preparative regimen for allogeneic transplant included cyclophosphamide 60 mg/kg i.v. Â 2 days followed by fractionated TBI 165 cGy b.i.d. (total 1320 cGy), using high-energy linear accelerator external beam irradiation. On day 0 (or þ 1 or 2 if added allogeneic collections were required), all collected PBSCs were infused. Graft-versushost disease prophylaxis included cyclosporine and shortcourse methotrexate.
Patients were restaged at day þ 28 and again at 3-monthly intervals during the first follow-up year and at 6-monthly intervals thereafter.
Evaluation of response
Response was assessed postpriming (prior to transplant, in autologous transplant recipients) and at day 28 day, 100 and 6 months and 1 year post transplant. The best attained response was considered. CR was defined as absence of monoclonal gammopathy in serum and urine electrophoresis, and 5% or fewer plasma cells in the marrow. Immunofixation was not routinely carried out and was not used for ascertainment of response. Partial response (PR) was defined as 50% or greater decrease in serum paraprotein and/or 90% decrease in urinary excretion of light-chain paraprotein. Minimal response (MR) required a less than 50% decrease in serum paraprotein and/or o90% decrease in urinary excretion of light-chain paraprotein. Stable disease was defined as no change in serum paraprotein or urinary light-chain excretion of paraprotein or bone marrow plasmacytosis. Relapse after CR was defined as reappearance of paraprotein or marrow plasma cell infiltration, or appearance of new lytic lesions, whereas progression required a 50% increase in measurable paraprotein.
Statistical analysis
Baseline demographic data and stage of disease at diagnosis, pretransplant chemotherapy, response to initial chemotherapy, dates of diagnosis and treatment, complications, survival times, causes of death and relapse were prospectively entered in the University of Minnesota Blood and Marrow Transplant database. This was supplemented by individual medical record reviews for hematologic recovery post transplant, complications and toxicity, and verification of response, relapse and progression. Primary end points of this study were OS and PFS. Secondary end points included CR and overall response (OR), relapse and nonrelapse mortality. Categorical baseline variables were compared using the w 2 test or Fisher's exact test, as appropriate. Continuous baseline characteristics were compared using Wilcoxon's rank sum test.
Response to therapy
Pearson's w 2 test was employed to compare the proportion of subjects attaining response in each group. Multivariate logistic regression was used to evaluate the independent effect of study variables on treatment response. A stepwise regression with forward selection was used.
Survival
Patient survival from the date of transplant was determined using the Kaplan-Meier estimation 12 with 95% confidence intervals derived from standard errors. Patients were censored at the date of last contact. Comparison of survival between the two treatment groups was carried out using the Kaplan-Meier plots and log-rank tests.
Predictors of mortality
Potential factors associated with effects on mortality were studied. The Kaplan-Meier product limit method was used to compare survival in the subsets, and the Cox regression model 13 was used to assess the independent effect of the predictors on survival. A stepwise regression with forward selection was used with a significance level of 0.1 to enter into the model and 0.15 to stay in the model.
Cumulative incidence rates 14 were used to estimate the probability of relapse or progression and response post transplant and nonrelapse mortality post transplant. Nonrelapse mortality was defined as death without prior relapse or progression regardless of cause.
Results
A total of 87 patients underwent high-dose therapy followed by PBSC transplant. A comparison of their clinical characteristics is given in Tables 1 and 2 . Patients who underwent autologous transplant were older (median age 53 years) than patients who received allogeneic transplant (median age 47 years). Non-IgG subtypes were significantly more frequent in the autologous transplant group (46%) than in the allogeneic transplant group (30%). In all, 37 and 24% of patients in the autologous and allogeneic groups received transplant after salvage chemotherapy, while the median time from diagnosis to transplant was 11 and 7 months for the two groups, respectively. Engraftment (ANC 4500/ml for two consecutive days) was faster in the autologous transplant group (median 10 vs 16 days in the allogeneic group).
Myeloma response to therapy
Response was assessed in 81 patients. Six patients (two in the autologous transplant group and four in the allogeneic transplant group) were not evaluable for response because of early (o120 days) post transplant mortality. In all, 43% [95% CI 33. .4%] of autologous and 39% [95% CI 14.5-62.5%] of allogeneic recipients had attained a CR or PR by 3 months post transplant. By 1 year, this increased (Figure 1b ).
Survival
After a median follow-up of 24 months (range 9-99 months) in the autologous transplant group and 43 months (range 10-81 months) in the allogeneic transplant group, the probability of OS was 86% [95% CI 80-95%] at 1 year and 50% [95% CI 34-66%] at 4 years in the autologous transplant group vs 64% [95% CI 40-87%] at both 1 and 4 years in the allogeneic transplant group (P ¼ 0.6) (Figure 2) . A plateau was attained after 1 year in the allogeneic transplant group with no deaths after 1 year post transplant. In patients surviving more than 1 year, OS was superior in the allogeneic transplant group (100 [95% CI 100%À100%] vs 58% [95% CI 41-75%] in the autologous transplant group (P ¼ 0.02) (Figure 3 (Figure 2 ). In patients surviving more than 1 year, allogeneic transplant patients had a trend toward superior PFS (56% [95% CI 17-95%] vs 27% [95% CI 8-46%] in the autologous transplant patients (P ¼ 0.1) (Figure 3) .
Relapse or progressive disease was seen in 41 (59%) autologous recipients at a median of 14 months (range 2-71 months) after transplant, and in five allogeneic recipients (29%) at a median of 13 months (range 3-43 months), P ¼ 0.9. Three of these five patients underwent donor lymphocyte infusion (DLI) 2-9 months after relapse. Two responded: one attaining a PR and the other a CR 3 and 7 months after therapy. The third patient had further progression of her disease and subsequently died 2 months after DLI. The cumulative incidence of relapse or disease progression ( Figure 4) A total of 30 patients (43%) died after autologous transplant and six (35%) patients died after allogeneic transplant. Progression of myeloma was a significantly more frequent cause of death in the autologous transplant group (n ¼ 25, 83%) vs in the allogeneic transplant group (n ¼ 2, 33%), Po0.01. Nine patients died of causes other than myeloma (five in the autologous transplant group and Autologous vs allogeneic PBSCT in multiple myeloma M Arora et al four in the allogeneic transplant group). Seven recipients (three autologous and four allogeneic) died within 120 days post transplant. Amongst the three autologous transplant recipients, one patient developed VOD and two died secondary to viral pneumonia þ aspergillus lung disease. Two of the allogeneic transplant recipients died secondary to infectious complications (one each with viral pneumonia and Gram-negative bacteremia) along with multiorgan failure, and two died secondary to acute graft-versus-host disease along with ARDS and multiorgan failure. Four patients in the autologous transplant group developed myelodysplastic syndrome (MDS). Two of these patients died, one secondary to toxoplasmosis and bacterial infection and the second underwent a nonmyeloablative allogeneic transplant 27 months after the autologous transplant and died 3 months later secondary to ARDS and acute graft-versus-host disease.
The cumulative incidence of nonrelapse mortality ( Figure 5 ) was significantly higher in the allogeneic than in the autologous transplant group: 18% [95% CI 0-36%] vs 4% [95% CI 0-9%] at 100 days and 31% [95% CI 9-53%] vs 6% [95% CI 0.4-11.4%] by 1 year (P ¼ 0.02).
Predictors of response and survival
We performed multiple regression analyses to identify variables associated with outcome. Variables considered included age at transplant, number of treatment regimens received pretransplant, number of cycles of pretransplant chemotherapy, stage of disease at diagnosis, myeloma subtype, time from diagnosis to transplant, response preand post transplant and type of transplant.
Predictors of good response
Patients who had received p2 regimens of pretransplant chemotherapy (odds ratio (OR) 8.3, [95% CI 2.2-31.3], Table 4 ). The same factors (CR or PR post transplant and p4 cycles of pretransplant chemotherapy) were also significant predictors of relapse-free survival (data not shown).
Predictors of nonrelapse mortality
Nonrelapse mortality was higher in patients with older age at transplant (RR 1.1 per year, [95% CI 0.9-1.3], P ¼ 0.06) and in patients who had received 44 cycles of pretransplant chemotherapy (RR 6.3, [95% CI 1.1-35.7], P ¼ 0.04). Nonrelapse mortality was also higher in patients who underwent allogeneic transplant (RR 11.0, [95% CI 2.3-53.7], Po0.01) ( Table 5) .
Myelodysplastic syndrome
Four patients (all in the autologous transplant group) developed MDS between 1 and 2 years post transplant. In these patients, the interval from diagnosis to transplant ranged from 1.3 to 6.8 years. All four patients had relapsed disease prior to transplant and had received a median of 9 (range 7-11) cycles of melphalan-based pretransplant chemotherapy. All four patients died (two of relapsed disease) at a median of 3.2 years (1.5-5.1 years) post transplant.
Discussion
High-dose myeloablative conditioning followed by autologous transplant has been associated with high rates of tumor regression and improved survival (median OS and PFS of 43-68 and 21-43 months, respectively). [1] [2] [3] [4] [5] [6] 15 In a recent study, Child et al 16 reported a randomized trial for newly diagnosed untreated patients with myeloma and observed superior OS of 54 vs 42 months and PFS of 31 vs 19 months for high-dose therapy and autografting vs conventional therapy. Tandem autologous transplantation has been reported to show favorable results, resulting in 48% CR and 58% surviving at 5 þ years from diagnosis. 4 A randomized comparison of single vs double autologous transplants in patients with early myeloma also showed superior results with double transplants. 5 A recent study by Segeren et al 17 reported good tolerance and similar efficacy of intensified chemotherapy compared to intensified chemotherapy followed by autologous transplant (OS and event-free survival of 47 vs 50 months and 21 vs 22 months, respectively); however, a higher CR (29 vs 13%) and longer time to progression (31 vs 25 months) were observed in patients randomized to the transplant arm. Despite these favorable observations, almost all patients eventually relapse or have progressive disease after autologous transplantation. In contrast, allogeneic transplant offers the potential for more durable remission through a graft vs myeloma effect. 7, 8 However, in previous studies, allogeneic transplantation has been associated with high TRM of 440%.
8
A recent update from the EBMT registry suggested a lower TRM of 21% at 6 months and 30% at 2 years in patients transplanted between 1994 and 1998 and an improved OS of 50 months. 7 However, in the same study, there was no decrease in the rate of relapse in the later time period (24 vs 23% at 2 years). Nonmyeloablative transplants may offer even lower TRM (1-year TRM of 15%), with OS of 78% at 18 months; 9 however, longer follow-up is needed to assess their net clinical utility. Relapse remains a major problem following either autologous or allogeneic transplant. In a study comparing results of autologous and allogeneic transplants from the EBMT registry, the relapse rates were 70 and 50% at 48 months (P ¼ 0.04) in the two groups, respectively. 8 However, the time until disease relapse or progression was significantly longer after allo-BMT compared to autologous stem cell transplant in patients alive at 1 year after transplant, indicating that the allogeneic graft may have some beneficial effect on the disease, which is probably lacking in autologous stem cell transplant. 8 We report an encouraging 4-year survival of 50% in the autologous transplant patients and 64% in the allogeneic transplant patients. Following allogeneic transplant, a plateau was seen in the survival curve with no deaths beyond 1 year. Disease progression was more frequent in the autologous group, but only modest nonrelapse mortality was seen in both groups. In patients surviving beyond 1 year, higher OS and PFS were seen in the allogeneic transplant patients, suggesting that allogeneic transplants may be better tolerated and more effective than previously reported. In the multiple regression analysis, p4 cycles of pretransplant chemotherapy and attainment of CR or PR post transplant were associated with superior OS and PFS. Our study is limited by the small number of allograft patients, some of whom showed favorable clinical characteristics (younger age, shorter time from diagnosis to transplant, IgG subtype). Nevertheless, in the series of patients treated with this approach, good tolerance and lower relapse rates were observed after allogeneic transplantation. Patients underwent transplant using cyclophosphamide and TBI as the conditioning regimen.
As suggested by previous studies, allogeneic transplant, at least for selected patients, appears to be the most likely way of obtaining extended disease control, with fewer and later relapses being observed post transplant. The higher TRM associated with allogeneic transplants has been a limiting factor, preventing wider application of this approach. However, as evidenced by our data, and by results from the EBMT 7 registry, the risk of TRM appears lower than that observed in previous studies. To identify a suitable group of patients for allogeneic transplants, we performed a multiple regression analysis to identify factors associated with a high nonrelapse mortality. Older age (per year) and 44 cycles of pretransplant chemotherapy were each independently significant in predicting a higher nonrelapse mortality. This suggests that younger patients, early after diagnosis and those with responsive disease pretransplant, may have a superior survival and lower nonrelapse mortality. This group may be suitable as candidates for allogeneic transplant. Thus, allogeneic transplants should still be considered for younger patients undergoing early transplants who have a matched sibling donor. Encouraging results have also been seen following tandem autologous transplants. Newer approaches, including nonmyeloablative allogeneic transplants, have been shown to be associated with lower TRM and are under further study. However, longer follow-up is needed to determine long-term survival and relapse rates using these techniques. A clinical trial comparing tandem autologous transplant to autologous transplant followed by nonmyeloablative allogeneic sibling donor transplant is under way.
